RVNC News and Press, Revance Therapeutics Inc. From 05/12/20

Privately held Galderma announces the results from a 120-subject study, DREAM, assessing the safety and patient satisfaction of Dysport (abobotulinumtoxinA) for the temporary treatment of moderate-to-severe glabellar lines (frown lines) between the eyebrows in adults less than 65 years old...

Revance Therapeutics, Inc. (RVNC) Q1 2020 Earnings Conference Call May 07, 2020 04:30 PM ET Company Participants Jeanie Herbert - Senior Director of Investor Relations and Corporate Communications Mark Foley - President and Chief Executive Officer Toby Schilke - Chief Financial ...

Image source: The Motley Fool. Revance Therapeutics   (NASDAQ: RVNC) Q1 2020 Earnings Call May 07, 2020 , 4:30 p.m. ET Operator Continue reading

Revance Therapeutics (NASDAQ: RVNC ): Q1 GAAP EPS of -$1.15 misses by $0.24 . More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Conference call and webcast today at 4:30 p.m. ET - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, today reported fi...

The FDA approves Galderma's Restylane Kysse, a hyaluronic acid filler, for lip augmentation and correction of upper perioral rhytids (wrinkles around the upper lip) in adults at least 21 years old. More news on: Allergan plc, Evolus, Inc., Revance Therapeutics, Inc., Healthcare stocks ne...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that it is continuing discussions with Mylan N.V. (NASD...

Conference Call Scheduled for Thursday, May 7, 2020 at 4:30 p.m. ET Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, tod...

Internationally renowned ophthalmologist, Gerd Auffarth, MD, ranked as one of the “100 most influential personalities in ophthalmology worldwide" in the 2020 Power List published by The Ophthalmologist  magazine Julian Gangolli, former President of the North American...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the company will participate in the 19th Annual Ne...